DA Davidson assumed coverage of Phreesia (PHR) with a Buy rating and $33 price target The firm believes Phreesia has the ability to address a broader scope of problems on behalf of providers, patients, and pharma companies, which it argues should translate to durable double-digit growth and ongoing margin expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia price target raised to $34 from $33 at Piper Sandler
- Phreesia price target raised to $38 from $34 at Canaccord
- Phreesia’s Strategic Growth and Financial Strength Justify Buy Rating Amidst AccessOne Acquisition
- Phreesia’s Strong Financial Performance and Strategic Acquisitions Justify Buy Rating
- Phreesia Reports First Net Income Positive Quarter